Qilu Pharmaceutical Co., Ltd.

Pharma

Jinan, Shandong, China · Est. 1995

Qilu Pharmaceutical is a Chinese pharmaceutical company focused on the research, development, and commercialization of innovative drugs across multiple therapeutic areas.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

189

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

45 drugs in development

Approved1

Phase 316

Phase 216

Phase 117

Preclinical3

By Therapeutic Area

top 6

Oncology

2646%

Neurology

35%

Cardiovascular

35%

Hematology

24%

Metabolic & Endocrine

24%

Psychiatry

12%

R&D Momentum

83/100

Pipeline Velocity

65/100

Trial Completion Rate

97/100

Pipeline Concentration

28/100

Pipeline Freshness

71/100

Strategic Signals

↗Active in Hematology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 16, 2026

Recruiting

A Phase 1 Study to Evaluate the C-QTc Interval of QLC5508, Compare the Pharmacokinetics of Two Different Formulations, and Assess Drug-Drug Interaction Potential in Participants With Advanced Solid Tumors

Sep 10, 2026

Recruiting

Phase 2/3 Randomized, Double-blind, Placebo-controlled Study of QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia.

Earlier

Sep 4, 2026TrialA Multicenter Study Evaluating the Efficacy and Safety of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer

Sep 4, 2026TrialA Phase III, Randomized, Controlled, Open-label Clinical Study to Compare the Efficacy and Safety of QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy as First-line Treatment in Participants With Extensive-stage Small Cell Lung Cancer

Sep 3, 2026TrialA Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Ascending Doses of QL2401 in Healthy Chinese Adult Participants

Aug 8, 2026TrialA Phase Ia/Ib Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases

Aug 6, 2026TrialA Randomized, Double-blinded, Parallel, Positive-controlled Study to Compare the Pharmacokinetic, Safety and Immunogenicity of Single-dose QL2106 vs Tremfye® in Healthy Subjects

Jul 30, 2026TrialA Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of QLS2319 for Injection/Placebo Following Single-Dose Administration in Healthy Subjects and Multiple-Dose Administration in Subjects With Cancer Cachexia.

4 more events

Jul 29, 2026TrialA Phase II Clinical Study Evaluating the Efficacy and Safety of QLS7305 in Patients With Primary IgA Nephropathy (IgAN), C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and Primary Membranous Nephropathy (PMN)